Background: Celiac disease (CD) is common but underdiagnosed in the United States. A proposed quality guideline recommends that Ն4 specimens be submitted during duodenal biopsy. The degree of adherence to this recommendation in clinical practice is unknown.
reduced after diagnosis and treatment with a gluten-free diet. [4] [5] [6] [7] [8] [9] [10] [11] Deficiencies in quality related to endoscopic evaluation may contribute to the low rates of diagnosis of CD in the United States. A multicenter endoscopy database study found that the majority of patients undergoing upper GI endoscopy for such indications as anemia, iron deficiency, and weight loss did not have a duodenal biopsy done during the procedure. 12 Because the histopathologic features of CD are patchy, guidelines recommend that 4 to 6 biopsy specimens of the small bowel be submitted during upper endoscopy when CD is under consideration. 1, 13 These proposed quality guidelines have been borne out by studies of patients with known CD, in which the sensitivity of duodenal biopsy was shown to decline when fewer than 4 specimens were examined. [14] [15] The degree to which endoscopists adhere to such recommendations in clinical practice and the diagnostic yield of adherence to this standard have not been studied.
By using a large, national, pathology database spanning the first 4 years during which these recommendations appeared (2006-2009), we assessed adherence to these proposed guidelines. To determine the diagnostic yield of the recommendation to submit Ն4 specimens, we investigated the association between adherence to this standard and the proportion of patients with the finding of a new diagnosis of CD. We also aimed to identify patient and procedure-related factors associated with the submission of Ն4 specimens. In so doing, this study elucidates how a guideline plays out in clinical practice, both in terms of adherence to the recommendation as well as the incremental yield of adherence.
METHODS

Study setting
The GI pathology division of Caris Life Sciences (Irving, Texas) is a specialized pathology laboratory that receives specimens from outpatient GI endoscopy centers in 43 states throughout the United States as well as the District of Columbia and Puerto Rico. Caris Life Sciences maintains a database of all patients who had endoscopic procedures in which a specimen was submitted to the laboratory. Patients and providers were de-identified in the preparation of the database for this analysis. For each specimen, the following is available: sex and age of the patient; procedure year, location, and provider; summary of the clinical history; endoscopic impressions; and histopathologic findings. For a subset of procedures, more detailed information on the indication for the examination and endoscopic findings are exported from the endoscopy report and are retrievable via free-text search.
Histopathologic criteria
In this laboratory, biopsies are interpreted by a group of GI pathologists who share a common approach to biopsy evaluation and use a predetermined approach to specimen handling, diagnostic criteria, and terminology.
Pathologic abnormalities of the duodenum in this laboratory are grouped in accordance with the classification developed by Marsh 16 and Oberhuber et al. 17 As in a previous analysis of yield of duodenal biopsy according to indication by using a subset of this data, 18 the following classification of outcomes was used: normal duodenal mucosa; duodenal intraepithelial lymphocytosis, as defined as Ͼ25 intraepithelial lymphocytes per 100 enterocytes, with or without crypt hypertrophy (equivalent to Marsh I or II lesions); blunted villi (Marsh IIIA); or flat villi (Marsh IIIB/C). Other recorded pathologic abnormalities include gastric metaplasia of the duodenal mucosa, regardless of the presence of Helicobacter pylori ("peptic duodenopathy" or "peptic duodenitis"), 19 and mild intraepithelial lymphocytosis (as indicated by the presence of intraepithelial lymphocytes not meeting the threshold for Marsh I).
Case identification
We queried the database for all small-intestine specimens retrieved during upper endoscopy on individuals aged Ն18 years during the 4-year period from January 1, 2006 to December 31, 2009. This query included any specimen labeled with the term duodenum, duodenal, small bowel, or small intestine and excluded any specimen that contained the word aspirate or aspiration so as to exclude fluid analysis from the dataset.
For individuals who underwent more than one examination during this period, we included only the first chronological examination. Because the primary aim was to assess biopsy practices in patients without known CD, we excluded any patient with a known history of CD as described in the clinical indication field. To determine the number of duodenal biopsy specimens for each biopsy set, we used a free-text search of the pathologist's description of each sample. When present, specimens from the duodenal bulb (identified either in the endoscopist's report or the histopathologic interpretation) were included
Take-home Message
• Adherence to the proposed standard of submitting Ն4 specimens occurred in only 35% of all endoscopies with duodenal biopsy. Adherence was less than 40%, even for those examinations in which the indication for endoscopy was malabsorption or suspected celiac disease.
• The probability of a new diagnosis of celiac disease more than doubled when Ն4 specimens were submitted.
in the total number of specimens submitted. Cases in which the number of specimens submitted was not quantified (either not stated or characterized as multiple) were excluded.
Data analysis
We used the chi-square test to assess the association between adherence to the recommendation of submitting Ն4 specimens and the proportion of patients with pathological findings consistent with CD. Because this dataset did not contain information on serological findings or follow-up clinical information, we defined a priori having a result of either blunted villi (Marsh IIIA) or flat villi (Marsh IIIB/C) as meeting the pathological definition of CD. For assessing the relationship between ordinal categories such as year or number of specimens and the pathologic diagnosis of CD, we used the CochranArmitage test for trend.
Given the possibility that gross endoscopic findings may be associated with both the number of specimens submitted and the probability of CD, we investigated the relationship between adherence to submitting Ն4 specimens and CD while stratifying by gross endoscopic findings. We used the Breslow-Day test for homogeneity of odds ratios (OR) so as to assess whether gross appearance modifies this association.
Generalized estimating equation multivariate logistic regression was used to determine factors associated with the submission of Ն4 specimens, adjusted for clustering by individual provider. We postulated that adherence to this practice was correlated with individual providers. Using the generalized estimating equation in this multivariate analysis takes such clustering into account when the variance of hypothesized associations is estimated.
We used SAS version 9.1 (Cary, NC) for all statistical calculations. All P values presented are 2-sided. The Institutional Review Board of Columbia University Medical Center evaluated this study protocol and designated it as "non-human subject research" involving de-identified records.
RESULTS
A total of 150,155 procedures involving a duodenal/ small-bowel biopsy were submitted for histopathologic evaluation during the 4-year period. Of these 150,155 procedures, 17,803 patients met at least one of the exclusion criteria: known CD at the start of the procedure (n ϭ 1841), repeated procedures (n ϭ 9531), and biopsies in which the number of specimens was not noted (n ϭ 7871). The remaining sample size for the analysis was 132,352.
Characteristics of the 132,352 patients included in the analysis are enumerated in Table 1 . It can be seen that 67% of the patients were women, and the mean (Ϯ standard deviation [SD]) age was 52.9 Ϯ 16.7 years. Gross abnormalities such as scalloping and decreased folds accounted for less than 2% of all gross descriptions.
Marsh I or II lesions were noted in 5944 individuals (4.5%), whereas Marsh IIIA was found in 819 (0.6%), and Marsh IIIB/C was found in 628 (0.5%). When a pathological diagnosis of CD was defined as blunted or flat villi (Marsh IIIA/B/C), a total of 1447 individuals (1.1%) were categorized as having CD.
The most common number of small-bowel specimens submitted during upper endoscopy was 2 (histogram; Fig.  1 ). The mean (Ϯ SD) number of specimens submitted was 3.1 Ϯ 1.6, and the median number submitted was 3. Of the 132,352 patients undergoing upper endoscopy with smallbowel biopsy, Ն4 small-bowel specimens were submitted in 45,995 patients (35%). The proportion of patients with Ն4 specimens submitted during endoscopy increased from 33.8% in 2006 to 37.2% in 2009 (P for trend Ͻ .0001).
Of the 45,995 individuals with Ն4 specimens submitted, a pathologic diagnosis of CD was present in 824 (1.8%), whereas among the 86,357 patients in whom Ͻ4 specimens were submitted, CD was present in 623 (0.7%; P Ͻ .0001). When treated as a continuous variable, the number of specimens submitted was directly correlated with the probability of a pathologic diagnosis of CD (Fig. 2) . Biopsy of the duodenal bulb was performed in 10% of patients; inclusion of a bulbar biopsy was not associated with an increased proportion of adherence to Ն4 small-bowel specimens (P ϭ .4309), nor was it associated with an increased probability of a pathological diagnosis of CD (OR 0.93; 95% confidence interval [CI], 0.78-1.11; P ϭ .4373).
Patients with abnormal gross duodenal findings on endoscopy had an increased prevalence of CD (3.2% vs 0.7%; OR 4.64; 95% CI, 3.80-5.67). The relationship between adherence to the standard of Ն4 specimens submitted and a pathologic diagnosis of CD stratified by gross endoscopic findings is presented in Table 2 . Gross endoscopic findings modified the association between number of specimens submitted and the prevalence of CD (Breslow-Day test for homogeneity of ORs: P ϭ .0015). This relationship was greater for those with abnormal gross findings (OR 3.67; 95% CI, 2.86-4.72) than for those with normal gross findings (OR 1.91; 95% CI, 1.38-2.63).
Among physicians who submitted duodenal biopsy specimens to this laboratory from at least 10 upper endoscopies during the study period (n ϭ 1243), the adherence rate to the proposed standard varied widely (mean adherence rate 38%, SD 27.8%). There was an adherence rate of between 0% and 10% for 19% of providers.
Adherence varied by indication (Table 3) , with highest rates among examinations performed for evaluation of diarrhea (43.9%) and lowest levels of adherence among procedures in which the indication was heartburn/GERD (30.0%). Among the different indications, the diagnostic yield of submitting Ն4 specimens was variable (Table 3) but remained significantly associated with increased odds of diagnosing CD for every indication. Of note, among patients whose only indication was malabsorption or suspected CD (n ϭ 3261), adherence to this quality standard occurred in 38.5% of examinations.
The results of generalized estimating equation multivariate analysis of factors associated with the submission of Ն4 specimens during upper endoscopy while adjusting for clustering by individual provider are shown in Table 4 . Patient age was associated with decreased odds of adherence, with individuals over 80 having the lowest odds of adherence compared with those younger than 30 (OR 0.67; 95% CI, 0.57-0.78). Clinical indication for endoscopy was significantly associated with the number of specimens submitted, with increased adherence to submitting Ն4 specimens for individuals with diarrhea (OR 1.20; 95% CI, 1.10-1.30) and malabsorption (OR 1.42; 95% CI, 1.10-1.85) and decreased adherence for patients undergoing endoscopy for dyspepsia (OR 0.78; 95% CI, 0.72-0.86) and heartburn (OR 0.78; 95% CI, 0.70-0.87). Abnormal gross findings were associated with decreased odds of submitting Ն4 specimens (OR 0.75; 95% CI, 0.69-0.81). The modest temporal trend of increased adherence to submitting Ն4 specimens remained significant in this multivariate analysis (OR for 2009 compared with 2006: 1.51; 95% CI, 1.22-1.88). 
DISCUSSION
In this analysis of a national pathology database of duodenal biopsies, 35% of patients had Ն4 specimens submitted during upper endoscopy. Adherence to this proposed standard 1,13 remained low even among those patients with malabsorption/suspected CD, with fewer than 40% of such patients having Ն4 specimens submitted. Regardless of indication, adherence to this proposed quality standard was associated with an increased rate of CD diagnosis.
This study evaluated the recommended practice of submitting Ն4 specimens when a diagnosis of CD is under consideration. 1, 13 This proposed guideline is new and subject to debate. As one recent review stated, "the optimal method of obtaining biopsies in patients with celiac disease is controversial." 20 This proposed guideline has not been established prospectively, and this recommendation stemmed instead from the observation that the histopathologic abnormalities of CD are patchy and can be missed entirely if an insufficient quantity of specimens is submitted. The recommendation was subsequently supported by a single-center retrospective study of 93 patients with CD, which found that 4 specimens led to a positive diagnosis in 100% of patients, whereas 2 specimens were diagnostic in only 90% of patients. 14 Those authors concluded that at least 4 duodenal biopsy specimens should be taken to rule out CD. A second study, investigating 56 patients with known CD, 15 found that 3 biopsy specimens were sufficient as long as 1 specimen was obtained from the duodenal bulb; however, 5 biopsy specimens were necessary to recognize the most severe extent of villous atrophy. These studies are limited by their small sample size and single-center settings.
To our knowledge, no previous study has evaluated the diagnostic yield of submitting Ն4 specimens for patients without known CD in accordance with these proposed guidelines. The incremental yield of submitting Ն4 specimens has not been evaluated in a population undergoing endoscopy for a variety of indications, in which only a small proportion of patients will have celiac disease, and in which such patients may have a more patchy distribu- tion of pathologic abnormalities. Moreover, adherence was low even for those who consider Ն3 specimens to be satisfactory, 20 because the most common submitted number of specimens was 2 (Fig. 1) . These results indicate that this proposed standard appears to be slowly diffusing into clinical practice, because the proportion of individuals undergoing duodenal biopsy who have Ն4 specimens submitted increased between the years 2006 and 2009. Nevertheless, this practice was performed in a minority of patients even in 2009, when only 37% of patients had Ն4 specimens submitted. Guidelines are adopted by physicians at variable rates, and at times this variability creates new racial or socioeconomic disparities. 21 In our study, we did not have access to socioeconomic or racial data to determine whether these individual patient characteristics were associated with the submission of the recommended number of specimens.
In this study, the incremental diagnostic yield of submitting Ն4 specimens was large, because the proportion of patients diagnosed with CD was doubled when Ն4 specimens were submitted. This incremental yield varied by indication and was greatest when the indication was malabsorption/suspected CD (OR 7.37; 95% CI, 4.70-11.57) or anemia (OR 2.65; 95% CI, 2.13-3.30). However, submitting Ն4 specimens also increased the diagnostic yield of CD even when the indication was GERD (OR 1.84; 95% CI, 1.33-2.55). We therefore conclude that, although the increased diagnostic yield of adherence varies in magnitude, it is present and should be adhered to regardless of indication.
Why were Ն4 specimens submitted only 35% of the time? One possibility is that this proposed guideline is new and not fully accepted. 1, 13, 20 Another possibility is that knowledge of the appropriate amount of specimens to submit is not yet widespread. This explanation is supported by the finding that the submission of Ն4 specimens has modestly increased over time (OR for 2009 vs 2006, 1.58; 95% CI, 1.27-1.97). A third contributing factor is the extra time involved in submitting additional specimens. The most common number of specimens submitted in this dataset was 2 (Fig. 1) . Two specimens usually can be collected by using one pass of the biopsy forceps. A second pass of the forceps, done for the purpose of collecting additional specimens, increases the length of the procedure. Although the amount of time for an additional pass of the biopsy forceps for additional biopsies is low (approximately 1 minute), the incremental yield of this additional time taken was heretofore unknown. Given the high incremental yield in the present analysis (resulting in a doubling of the proportion of patients with a pathological diagnosis of CD), the proposed standard of submitting Ն4 specimens appears to be justified.
We observed a marked variability between individual endoscopists with regard to the proportion of examinations in which the recommended number of specimens was submitted. Although the mean adherence rate among providers was 38.3%, the most common percentage adherence per individual was between 0% and 10%. The wide variability in adherence to this recommendation is reminiscent of the variability of a familiar quality indicator in gastroenterology, the adenoma detection rate in screening colonoscopy. 22 The discovery of that variability and associated predictive factors such as colonoscope withdrawal time 23 has led to a focus on high-quality colonoscopy as a priority for the profession of gastroenterology. 24 The findings in the present study, of low adherence to a recommendation in the face of a high diagnostic yield of submitting Ն4 specimens, should spur efforts to increase adherence to this standard. This study has several limitations. This was a retrospective analysis of a pathology tissue database, which has nevertheless yielded high-quality analyses of GI epidemiology and quality measures. [25] [26] In this database, we did not have access in all patients to key variables that influence the likelihood of CD, such as data regarding family history of CD or serology results. Those with positive CD serology results (ie, noted in the clinical indication field) were classified in the "suspected CD" indication category; this variable was included in the multivariate analysis. Information regarding the type of sedation used during the procedure and degree of sedation, which may have impacted the ability to obtain Ն4 specimens, was not available. The diagnosis of CD in this study was based strictly on histopathologic findings, and reliance on histology alone has been criticized for its lack of specificity. 27 For this reason, we considered only the most severe histopathologic changes (Marsh III lesions) as CD, excluding the increasingly common report of increased intraepithelial lymphocytosis, so as to maximize the specificity of the outcome in this analysis.
Certain providers may have a particular interest or expertise in CD and thus are more likely to submit Ն4 specimens. We therefore performed the generalized estimating equation multivariate analysis, adjusting for clustering by individual provider. The fact that the association between the number of specimens submitted and the diagnosis of CD is magnified when those high pretest probability strata (such as gross abnormal appearance or indication of suspected CD/ malabsorption) are examined supports the argument that the relationship between submitting Ն4 specimens and an increased probability of CD is causal and robust.
We conclude that Ն4 specimens are submitted during the procedure only in the minority of individuals undergoing upper GI endoscopy with duodenal biopsy in the United States. Even among those patients with an indication for endoscopy of malabsorption or suspected CD (including positive serology results), adherence to this proposed standard occurred in only 38.5% of examinations. The additional diagnostic yield of submitting Ն4 specimens varies by indication and gross appearance but is in all cases associated with an increased probability of a diagnosis of CD. Given the high incremental yield of submitting Ն4 specimens, efforts to increase adherence to this standard are warranted.
